Human umbilical cord blood-derived mesenchymal stem cells inhibit C6 glioma via downregulation of cyclin D1

Hongliang Jiao, Fangxia Guan, Bo Yang, Jianbin Li, Hong Shan, Laijun Song, Xiang Hu, Ying Du

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aims and Background: Glioma is difficult to treat and despite advances, outcomes remain poor and new treatment modalities are required. We studied the inhibitive effects of human umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) on glioma growth. Material and Methods: UCB-MSCs were identified in mice by flow cytometric analysis, and neurogenic differentiation by immunohistochemistry. C6 cells were injected subcutaneously into the posterior right flank of each mouse. Dil-labeled UCB-MSCs were administrated by intravenous (IV) or intratumoral (IT) injection. Tumor blood vessel density was detected by counting the number of CD34-positive cells with endothelial morphology. Cyclin D1 protein expression was detected by immunohistochemistry and Western blot analysis. Results: A 26% reduction in overall tumor volume was observed after IV UCB-MSCs treatment, 36% in animals who received IT UCB-MSCs. UCB-MSC administration was associated with reduced neovascularization. We identified a 48% and 27% reduction in the number of cyclin D1-positive cells in mouse glioma tissues treated with UCB-MSCs IV and IT, respectively. Conclusion: We demonstrated that UCB-MSCs potently inhibit glioma growth, reduce neovascularization, and decrease cyclin D1 protein expression in vivo. IV or IT UCB-MSC administration significantly inhibits glioma growth, and may represent a promising new therapy.

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalNeurology India
Volume59
Issue number2
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Cyclin D1
Mesenchymal Stromal Cells
Fetal Blood
Glioma
Down-Regulation
Growth
Immunohistochemistry
Vascular Tissue Neoplasms
faropenem medoxomil
Tumor Burden
Proteins
Therapeutics
Endothelial Cells
Western Blotting
Injections

Keywords

  • C6 glioma
  • inhibition
  • mesenchymal stem cells
  • Umbilical cord blood

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Human umbilical cord blood-derived mesenchymal stem cells inhibit C6 glioma via downregulation of cyclin D1. / Jiao, Hongliang; Guan, Fangxia; Yang, Bo; Li, Jianbin; Shan, Hong; Song, Laijun; Hu, Xiang; Du, Ying.

In: Neurology India, Vol. 59, No. 2, 03.2011, p. 241-247.

Research output: Contribution to journalArticle

Jiao, Hongliang ; Guan, Fangxia ; Yang, Bo ; Li, Jianbin ; Shan, Hong ; Song, Laijun ; Hu, Xiang ; Du, Ying. / Human umbilical cord blood-derived mesenchymal stem cells inhibit C6 glioma via downregulation of cyclin D1. In: Neurology India. 2011 ; Vol. 59, No. 2. pp. 241-247.
@article{f4e6ff62f15f4fccb609bf316dae25eb,
title = "Human umbilical cord blood-derived mesenchymal stem cells inhibit C6 glioma via downregulation of cyclin D1",
abstract = "Aims and Background: Glioma is difficult to treat and despite advances, outcomes remain poor and new treatment modalities are required. We studied the inhibitive effects of human umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) on glioma growth. Material and Methods: UCB-MSCs were identified in mice by flow cytometric analysis, and neurogenic differentiation by immunohistochemistry. C6 cells were injected subcutaneously into the posterior right flank of each mouse. Dil-labeled UCB-MSCs were administrated by intravenous (IV) or intratumoral (IT) injection. Tumor blood vessel density was detected by counting the number of CD34-positive cells with endothelial morphology. Cyclin D1 protein expression was detected by immunohistochemistry and Western blot analysis. Results: A 26{\%} reduction in overall tumor volume was observed after IV UCB-MSCs treatment, 36{\%} in animals who received IT UCB-MSCs. UCB-MSC administration was associated with reduced neovascularization. We identified a 48{\%} and 27{\%} reduction in the number of cyclin D1-positive cells in mouse glioma tissues treated with UCB-MSCs IV and IT, respectively. Conclusion: We demonstrated that UCB-MSCs potently inhibit glioma growth, reduce neovascularization, and decrease cyclin D1 protein expression in vivo. IV or IT UCB-MSC administration significantly inhibits glioma growth, and may represent a promising new therapy.",
keywords = "C6 glioma, inhibition, mesenchymal stem cells, Umbilical cord blood",
author = "Hongliang Jiao and Fangxia Guan and Bo Yang and Jianbin Li and Hong Shan and Laijun Song and Xiang Hu and Ying Du",
year = "2011",
month = "3",
doi = "10.4103/0028-3886.79134",
language = "English (US)",
volume = "59",
pages = "241--247",
journal = "Neurology India",
issn = "0028-3886",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Human umbilical cord blood-derived mesenchymal stem cells inhibit C6 glioma via downregulation of cyclin D1

AU - Jiao, Hongliang

AU - Guan, Fangxia

AU - Yang, Bo

AU - Li, Jianbin

AU - Shan, Hong

AU - Song, Laijun

AU - Hu, Xiang

AU - Du, Ying

PY - 2011/3

Y1 - 2011/3

N2 - Aims and Background: Glioma is difficult to treat and despite advances, outcomes remain poor and new treatment modalities are required. We studied the inhibitive effects of human umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) on glioma growth. Material and Methods: UCB-MSCs were identified in mice by flow cytometric analysis, and neurogenic differentiation by immunohistochemistry. C6 cells were injected subcutaneously into the posterior right flank of each mouse. Dil-labeled UCB-MSCs were administrated by intravenous (IV) or intratumoral (IT) injection. Tumor blood vessel density was detected by counting the number of CD34-positive cells with endothelial morphology. Cyclin D1 protein expression was detected by immunohistochemistry and Western blot analysis. Results: A 26% reduction in overall tumor volume was observed after IV UCB-MSCs treatment, 36% in animals who received IT UCB-MSCs. UCB-MSC administration was associated with reduced neovascularization. We identified a 48% and 27% reduction in the number of cyclin D1-positive cells in mouse glioma tissues treated with UCB-MSCs IV and IT, respectively. Conclusion: We demonstrated that UCB-MSCs potently inhibit glioma growth, reduce neovascularization, and decrease cyclin D1 protein expression in vivo. IV or IT UCB-MSC administration significantly inhibits glioma growth, and may represent a promising new therapy.

AB - Aims and Background: Glioma is difficult to treat and despite advances, outcomes remain poor and new treatment modalities are required. We studied the inhibitive effects of human umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) on glioma growth. Material and Methods: UCB-MSCs were identified in mice by flow cytometric analysis, and neurogenic differentiation by immunohistochemistry. C6 cells were injected subcutaneously into the posterior right flank of each mouse. Dil-labeled UCB-MSCs were administrated by intravenous (IV) or intratumoral (IT) injection. Tumor blood vessel density was detected by counting the number of CD34-positive cells with endothelial morphology. Cyclin D1 protein expression was detected by immunohistochemistry and Western blot analysis. Results: A 26% reduction in overall tumor volume was observed after IV UCB-MSCs treatment, 36% in animals who received IT UCB-MSCs. UCB-MSC administration was associated with reduced neovascularization. We identified a 48% and 27% reduction in the number of cyclin D1-positive cells in mouse glioma tissues treated with UCB-MSCs IV and IT, respectively. Conclusion: We demonstrated that UCB-MSCs potently inhibit glioma growth, reduce neovascularization, and decrease cyclin D1 protein expression in vivo. IV or IT UCB-MSC administration significantly inhibits glioma growth, and may represent a promising new therapy.

KW - C6 glioma

KW - inhibition

KW - mesenchymal stem cells

KW - Umbilical cord blood

UR - http://www.scopus.com/inward/record.url?scp=79955409834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955409834&partnerID=8YFLogxK

U2 - 10.4103/0028-3886.79134

DO - 10.4103/0028-3886.79134

M3 - Article

C2 - 21483126

AN - SCOPUS:79955409834

VL - 59

SP - 241

EP - 247

JO - Neurology India

JF - Neurology India

SN - 0028-3886

IS - 2

ER -